Dr Philippe Dro
United States of America
Dr. Dro has 20 years of entrepreneurial experience in the life science industry, including a pivotal role in executing strategic transactions at several biotech and medtech companies. He has been CEO and a Member of the Supervisory Board of GlycoVaxyn AG since May 2008. Previously, Dr. Dro was CEO and Chairman of Endoart SA, a medtech company developing telemetry-driven implants for cardiac disease and obesity that was sold to Allergan, Inc. Dr. Dro received a doctorate in Pharmacy (Pharm D) from the School of Pharmacy of the University of Grenoble, France, and holds a joint MBA from Ecole Superieure de Commerce de Lyon, France, and Cranfield School of Management, United Kingdom.